Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC
Leukemia in press Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study
comparing acalabrutinib with or without obinutuzumab versus obinutuzumab
plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
January 1, 2022 at 12:00 AM